Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).

Philippe Moreau,A. Keith Stewart,Meletios A. Dimopoulos,David Samuel DiCapua Siegel,Thierry Facon,James R. Berenson,Noopur S. Raje,Jesus G. Berdeja,Robert Z. Orlowski,Hui Yang,Haijun Ma,Zandra Karina Klippel,Anita Zahlten-Kumeli,Khalid Mezzi,Karim Iskander,Maria-Victoria Mateos

Journal of Clinical Oncology（2019）

Cited 0|Views56

No score

Abstract

e19505Background: CFZ combined with dexamethasone is approved to treat pts with RRMM, with CFZ given once-weekly at 70 mg/m2 (Kd70 QW) or twice-weekly at 56 mg/m2 (Kd56 BIW). No randomized trials h...

Translated text

Key words

refractory multiple myeloma,carfilzomib,dosing,cfz,once-weekly,twice-weekly

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined